← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS › Centrally acting sympathomimetics
solriamfetol
N06BA14
Forms & Strengths
- Oral tablets: 75 mg
- Oral tablets: 150 mg
- Oral tablets: 75 mg (starter pack)
- Oral tablets: 150 mg (starter pack)
Adult Dosing
- Narcolepsy: Initial 37.5 mg once daily upon awakening; may increase at intervals of at least 3 days to maximum 150 mg once daily
- Obstructive Sleep Apnea (OSA): Initial 37.5 mg once daily upon awakening; may increase at intervals of at least 3 days to maximum 150 mg once daily
- Renal impairment (CrCl 30-59 mL/min): Initial 37.5 mg once daily; max 75 mg once daily
- Renal impairment (CrCl 15-29 mL/min): Initial 37.5 mg once daily; max 37.5 mg once daily
- Renal impairment (CrCl <15 mL/min): Not recommended
Pediatric Dosing
- Safety and effectiveness in pediatric patients below 18 years of age have not been established
Indications
- Improvement of wakefulness in adults with excessive daytime sleepiness associated with narcolepsy
- Improvement of wakefulness in adults with excessive daytime sleepiness associated with obstructive sleep apnea (OSA)
Mechanism of Action
- Dopamine and norepinephrine reuptake inhibitor (DNRI)
- Binds to the dopamine transporter (DAT) and norepinephrine transporter (NET) with high affinity
- Inhibits the reuptake of dopamine and norepinephrine, increasing extracellular concentrations of these neurotransmitters
Contraindications
- Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days following discontinuation of an MAOI
- Known hypersensitivity to solriamfetol or any inactive ingredients
Adverse Reactions
- Headache
- Nausea
- Decreased appetite
- Nasopharyngitis
- Insomnia
- Anxiety
- Increased blood pressure
- Increased heart rate
- Dry mouth
- Diarrhea
Drug Interactions
- Monoamine oxidase inhibitors (MAOIs): Risk of hypertensive crisis; do not use concurrently or within 14 days
- Dopaminergic drugs and stimulants: May potentiate cardiovascular effects or increase risk of psychiatric adverse events
- Blood pressure-increasing agents: May enhance hypertensive effects, monitor BP closely
Curated Content: Needs Vetting Before Put to Clinical Use